Quick Answer
Cabaletta Bio, Inc. reported Net Income of -$167.86 million for fiscal year 2025.
Cabaletta Bio, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Net Income | -$167.86M -44.9% |
-$115.86M -71.2% |
-$67.67M -27.7% |
-$52.98M -14.4% |
-$46.29M -38.8% |
-$33.34M -96.8% |
| Diluted EPS | -$2.10 +10.3% |
-$2.34 -41.8% |
-$1.65 +8.8% |
-$1.81 -0.6% |
-$1.80 | — |
| Total Assets | $165.08M -10.8% |
$185.05M -27.0% |
$253.65M +116.9% |
$116.97M -7.4% |
$126.34M +10.1% |
$114.72M -18.9% |
| Cash and Equivalents | $82.98M -49.4% |
$163.96M -15.2% |
$193.24M +136.8% |
$81.61M -33.2% |
$122.22M +20.5% |
$101.43M -25.5% |
| Stockholders Equity | $112.05M -26.4% |
$152.34M -35.5% |
$236.20M +126.0% |
$104.52M -11.4% |
$117.96M +7.7% |
$109.54M -20.8% |
| R&D Expense | $142.67M +46.8% |
$97.20M +75.4% |
$55.42M +41.0% |
$39.30M +20.9% |
$32.49M +52.0% |
$21.38M +83.2% |
| Operating Income | -$172.24M -37.6% |
-$125.14M -67.6% |
-$74.66M -37.9% |
-$54.14M -16.9% |
-$46.31M -36.9% |
-$33.83M -81.1% |
| Shares Outstanding | 100.48M +98.0% |
50.74M +6.1% |
47.82M +62.4% |
29.45M +1.8% |
28.93M +20.2% |
24.06M +0.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$44.87M | -46.5% | +0.6% |
| Diluted EPS | September 30, 2025 | -$0.44 | +29.0% | +39.7% |
| Total Assets | September 30, 2025 | $189.76M | -7.2% | -15.5% |
| Cash and Equivalents | September 30, 2025 | $60.21M | -64.7% | -58.7% |
| Stockholders Equity | September 30, 2025 | $139.47M | -20.0% | -21.9% |
| R&D Expense | September 30, 2025 | $39.82M | +51.5% | +5.8% |
| Operating Income | September 30, 2025 | -$46.59M | -41.0% | -1.5% |
| Shares Outstanding | September 30, 2025 | 96.27M | +97.1% | +5.3% |
- Cabaletta Bio, Inc. reported Net Income of -$167.86 million for fiscal year 2025.
- Cabaletta Bio, Inc. showed a decrease of -44.9% in Net Income compared to the prior fiscal year.
- Cabaletta Bio, Inc. reported Diluted EPS of $2.10 per share (loss) for fiscal year 2025.
- Cabaletta Bio, Inc. showed an increase of +10.3% in Diluted EPS compared to the prior fiscal year.
- Cabaletta Bio, Inc. reported Total Assets of $165.08 million for fiscal year 2025.
- Cabaletta Bio, Inc. showed a decrease of -10.8% in Total Assets compared to the prior fiscal year.
- Cabaletta Bio, Inc. reported Cash and Equivalents of $82.98 million for fiscal year 2025.
- Cabaletta Bio, Inc. showed a decrease of -49.4% in Cash and Equivalents compared to the prior fiscal year.
- Cabaletta Bio, Inc. reported Stockholders Equity of $112.05 million for fiscal year 2025.
- Cabaletta Bio, Inc. showed a decrease of -26.4% in Stockholders Equity compared to the prior fiscal year.
- Cabaletta Bio, Inc. reported R&D Expense of $142.67 million for fiscal year 2025.
- Cabaletta Bio, Inc. showed an increase of +46.8% in R&D Expense compared to the prior fiscal year.
- Cabaletta Bio, Inc. reported Operating Income of -$172.24 million for fiscal year 2025.
- Cabaletta Bio, Inc. showed a decrease of -37.6% in Operating Income compared to the prior fiscal year.
- Cabaletta Bio, Inc. reported Shares Outstanding of 100.48 million shares for fiscal year 2025.
- Cabaletta Bio, Inc. showed an increase of +98.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: